<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248297</url>
  </required_header>
  <id_info>
    <org_study_id>CHI UAB MISP # 54628</org_study_id>
    <nct_id>NCT03248297</nct_id>
  </id_info>
  <brief_title>Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries</brief_title>
  <official_title>Azithromycin With or Without Amoxicillin to Prevent Peripartum Infection and Sepsis in Laboring High-risk Women: 3-Arm RCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study, performed over a course of 3 years in 5 collaborating hospitals in Cameroon,
      Africa, will randomize 750 women in labor with prolonged rupture of membranes ≥ 12 hours or
      prolonged labor ≥ 24 hours to 1 gram of oral azithromycin, 1 gram of azithromycin+2 grams of
      amoxicillin, compared to usual care (placebo). Women will be followed to ascertain maternal
      infectious outcomes and perinatal outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 3-arm study is a large randomized clinical trial designed to evaluate the comparative
      effectiveness and safety of single dose oral azithromycin or combined
      azithromycin+amoxicillin compared to placebo for the prevention of peripartum infections and
      sepsis in laboring women. We have previously shown the effectiveness of azithromycin for
      extended spectrum antibiotic prophylaxis in addition to the standard cephalosporin alone for
      reduction of post-cesarean infections. In LICs, the fraction of maternal infection and sepsis
      from cesarean delivery is minimal. Therefore, it is necessary to evaluate strategies aimed at
      reducing these morbidities in women who have vaginal births. There is an increased risk of
      infection in women who have prolonged labor or prolonged rupture of membranes. Drawing from
      our findings with azithromycin-based extended antibiotic prophylaxis for cesarean delivery,
      we propose to adapt the intervention and evaluate a single oral dose of azithromycin (with or
      without oral amoxicillin) to prevent maternal peripartum infection and sepsis. This study,
      performed over a course of 3 years in 5 collaborating hospitals in Cameroon, Africa, will
      randomize 750 women in labor with prolonged rupture of membranes ≥ 12 hours or prolonged
      labor ≥ 24 hours to 1 gram of oral azithromycin, 1 gram of azithromycin+2 grams of
      amoxicillin, compared to usual care (placebo). Women will be followed to ascertain maternal
      infectious outcomes and perinatal outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripartum infection</measure>
    <time_frame>Up to 6 weeks after delivery</time_frame>
    <description>Maternal peripartum infection including chorioamnionitis, endometritis, wound infection, sepsis, deep infection, pneumonia or pyelonephritis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Newborn infection</measure>
    <time_frame>Up to 6 weeks after hospital discharge</time_frame>
    <description>Newborn infection including sepsis, pneumonia, meningitis, urinary infection</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Postpartum Sepsis</condition>
  <condition>Postpartum Endometritis</condition>
  <condition>Postpartum Fever</condition>
  <arm_group>
    <arm_group_label>Azithromycin and amoxicillin placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive 1 gram oral azithromycin as a single dose and amoxicillin placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin + amoxicillin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will receive 1 gram oral azithromycin and 2 grams oral amoxicillin in a single dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will consist of routine care at the clinical sites (which is usually no antibiotic). They will receive placebo (for azithromycin) and placebo (for amoxicillin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin tablet</description>
    <arm_group_label>Azithromycin and amoxicillin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin and amoxicillin</intervention_name>
    <description>azithromycin and amoxicillin</description>
    <arm_group_label>Azithromycin + amoxicillin</arm_group_label>
    <other_name>azithromycin, amoxicillin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet</description>
    <arm_group_label>Azithromycin and amoxicillin placebo</arm_group_label>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women ≥ 37 weeks' viable singleton or twin gestation in labor planning a vaginal
             delivery with

               1. Prolonged membrane rupture (&gt;=12 hours) or

               2. Prolonged labor (&gt;=24 hours).

        Exclusion Criteria:

          -  Clinical chorioamnionitis or any other active bacterial infection (e.g.
             pyelonephritis, pneumonia, abscess) at time of randomization: because standard
             antibiotic therapy for these conditions may confound trial intervention.

          -  Allergy to azithromycin or amoxicillin

          -  Plan for cesarean delivery prior to enrollment

          -  Fetal demise or major congenital anomaly: Major congenital anomalies may confound
             assessment of neonatal outcomes and every attempt will be made up front to exclude
             them from randomization. However, some unrecognized fetal anomalies may inevitably be
             randomized. These will not be excluded post-randomization from the primary (maternal
             outcome) analysis; they will be taken into consideration in the secondary analyses of
             neonatal outcomes.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Tita, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akila Subramaniam, MD, MPH</last_name>
    <phone>205-934-5611</phone>
    <email>asubramaniam@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alan Tita, MD, PhD</last_name>
    <phone>205-934-5611</phone>
    <email>atita@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cameroon Baptist Convention Health Services</name>
      <address>
        <city>Bamenda</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pius Tih, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <reference>
    <citation>Tita ATN, Boggess K, Saade G. Adjunctive Azithromycin Prophylaxis for Cesarean Delivery. N Engl J Med. 2017 Jan 12;376(2):182. doi: 10.1056/NEJMc1614626.</citation>
    <PMID>28076707</PMID>
  </reference>
  <reference>
    <citation>WHO. WHO recommendations for prevention and treatment of maternal peripartum infections. Sept 2015 http://www.who.int/reproductivehealth/publications/maternal_perinatal_health/peripartum-infections-guidelines/en/</citation>
  </reference>
  <results_reference>
    <citation>Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96.</citation>
    <PMID>10196487</PMID>
  </results_reference>
  <results_reference>
    <citation>ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery. American Society of Health-System Pharmacists. Am J Health Syst Pharm. 1999 Sep 15;56(18):1839-88. Review.</citation>
    <PMID>10511234</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>January 18, 2018</last_update_submitted>
  <last_update_submitted_qc>January 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Alan Tita</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Endometritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

